Shares of Futura Medical plc (LON:FUM – Get Free Report) dropped 10.1% during trading on Monday . The stock traded as low as GBX 2.10 ($0.03) and last traded at GBX 2.20 ($0.03). Approximately 3,145,382 shares changed hands during trading, an increase of 201% from the average daily volume of 1,043,410 shares. The stock had previously closed at GBX 2.44 ($0.03).
Futura Medical Trading Down 9.9%
The company’s fifty day moving average is GBX 7.65 and its 200 day moving average is GBX 8.88. The company has a market cap of £6.69 million, a P/E ratio of -105.77 and a beta of 1.25.
Futura Medical (LON:FUM – Get Free Report) last announced its quarterly earnings results on Tuesday, September 30th. The company reported GBX (2.17) earnings per share (EPS) for the quarter. Futura Medical had a negative return on equity of 56.44% and a negative net margin of 44.64%. Analysts anticipate that Futura Medical plc will post 2.8486672 EPS for the current year.
About Futura Medical
Futura Medical plc, a pharmaceutical company, develops pharmaceutical and healthcare products for the consumer healthcare markets focusing on sexual health and pain relief management. Its lead product is MED3000, a topical gel for the treatment of erectile dysfunction. The company also develops pain relief products, including TPR100, a topical diclofenac pain relief gel; CBD100, a topical cannabidiol formulation; and TIB200, a topical ibuprofen pain relief gel.
Featured Stories
- Five stocks we like better than Futura Medical
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Microsoft 365 Premium Marks the Next Phase of AI Monetization
- 3 Best Fintech Stocks for a Portfolio Boost
- Could Target’s Week of Discounts Come Full Circle for Investors?
- Trading Stocks: RSI and Why it’s Useful
- 3 Reasons to Buy Sprouts Farmers Market Ahead of Earnings
Receive News & Ratings for Futura Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Futura Medical and related companies with MarketBeat.com's FREE daily email newsletter.